The need for efficient and innovative drug discovery chemistry strategies to support novel modalities like Degraders, ADCs (Antibody-Drug Conjugates), and other complex therapeutics has never been greater.
In this webinar, Eurofins Discovery’s global team of chemistry experts will share how integrated, AI-enhanced workflows and high-throughput methods are accelerating the development of robust candidates. Drawing on our proven expertise in medicinal, computational, synthetic, and analytical chemistry, we’ll explore how our streamlined, automation-driven approach enables the rapid delivery of potent, high-quality compounds, while ensuring IP protection and cost efficiency.
The session will highlight real-world applications of these capabilities, including the story of an A2A receptor program that progressed from early-stage discovery to preclinical candidate nomination for Parkinson’s Disease, and was later successfully repositioned for Immuno-Oncology. We’ll also explore how our chemistry strategies are enabling the development of complex modalities such as degraders and ADCs, demonstrating the scalability and precision of our approach across diverse therapeutic platforms.
Whether you're working on traditional small molecules or next-generation biologically targeted therapies, this session will help you identify practical strategies to reduce risk, enhance translational success, and accelerate your discovery pipeline.
Key Learning Objectives:
- Leverage integrated chemistry platforms support to accelerate iteration and decision-making across modalities, including NCEs, ADCs, and hybrids
- Apply innovative approaches to payload-linker synthesis and conjugation in ADCs development
- Discover advanced tools and techniques to speed up hit-to-lead transitions and lead optimization
- Explore case studies that demonstrate successful implementation of discovery strategies
- Enhance efficiency, reduce attrition, and improve candidate quality through streamlined chemistry workflows